Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 3
1955 1
1956 2
1957 2
1958 5
1959 2
1960 1
1961 1
1962 1
1963 1
1964 2
1965 1
1966 2
1967 4
1968 2
1969 7
1970 6
1971 6
1972 8
1973 5
1974 3
1975 1
1976 1
1977 1
1978 5
1979 8
1980 7
1981 8
1982 9
1983 4
1984 4
1985 7
1986 11
1987 2
1988 8
1989 6
1990 8
1991 5
1992 12
1993 10
1994 17
1995 19
1996 18
1997 16
1998 20
1999 26
2000 24
2001 27
2002 25
2003 28
2004 25
2005 24
2006 23
2007 25
2008 17
2009 18
2010 20
2011 19
2012 23
2013 18
2014 21
2015 23
2016 27
2017 17
2018 18
2019 21
2020 16
2021 14
2022 21
2023 6
Text availability
Article attribute
Article type
Publication date

Search Results

743 results
Results by year
Filters applied: . Clear all
Page 1
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. Among authors: bergeron j. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Wei AH, et al. Among authors: bergeron j. Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856. Blood. 2020. PMID: 32219442 Free PMC article. Clinical Trial.
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J, Szamosi T, Santra S, Stefanutti C, Descamps OS, Greber-Platzer S, Luirink I, Kastelein JJP, Gaudet D; HAUSER-RCT Investigators. Santos RD, et al. Among authors: bergeron j. N Engl J Med. 2020 Oct 1;383(14):1317-1327. doi: 10.1056/NEJMoa2019910. Epub 2020 Aug 29. N Engl J Med. 2020. PMID: 32865373 Clinical Trial.
A family of conserved bacterial virulence factors dampens interferon responses by blocking calcium signaling.
Alphonse N, Wanford JJ, Voak AA, Gay J, Venkhaya S, Burroughs O, Mathew S, Lee T, Evans SL, Zhao W, Frowde K, Alrehaili A, Dickenson RE, Munk M, Panina S, Mahmood IF, Llorian M, Stanifer ML, Boulant S, Berchtold MW, Bergeron JRC, Wack A, Lesser CF, Odendall C. Alphonse N, et al. Among authors: bergeron jrc. Cell. 2022 Jun 23;185(13):2354-2369.e17. doi: 10.1016/j.cell.2022.04.028. Epub 2022 May 13. Cell. 2022. PMID: 35568036 Free PMC article.
mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1.
Morita M, Prudent J, Basu K, Goyon V, Katsumura S, Hulea L, Pearl D, Siddiqui N, Strack S, McGuirk S, St-Pierre J, Larsson O, Topisirovic I, Vali H, McBride HM, Bergeron JJ, Sonenberg N. Morita M, et al. Among authors: bergeron jj. Mol Cell. 2017 Sep 21;67(6):922-935.e5. doi: 10.1016/j.molcel.2017.08.013. Epub 2017 Sep 14. Mol Cell. 2017. PMID: 28918902 Free article.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Robinson JG, et al. Among authors: bergeron j. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773378 Free article. Clinical Trial.
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O'Dea L, Bruckert E. Witztum JL, et al. Among authors: bergeron j. N Engl J Med. 2019 Aug 8;381(6):531-542. doi: 10.1056/NEJMoa1715944. N Engl J Med. 2019. PMID: 31390500 Clinical Trial.
Zygomatic Arch Fracture.
Bergeron JM, Raggio BS. Bergeron JM, et al. 2022 Jun 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. 2022 Jun 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31751088 Free Books & Documents.
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA; ODYSSEY ALTERNATIVE Investigators. Moriarty PM, et al. Among authors: bergeron j. J Clin Lipidol. 2015 Nov-Dec;9(6):758-769. doi: 10.1016/j.jacl.2015.08.006. Epub 2015 Aug 29. J Clin Lipidol. 2015. PMID: 26687696 Free article. Clinical Trial.
743 results